POLR2A encodes the largest subunit of RNA polymerase II, which makes RNA from DNA. Researchers study whether losing one gene copy creates a vulnerability to further suppression.
RNA polymerase II is a transcription complex; POLR2A encodes its largest catalytic subunit. Amanitin inhibits the complex. This intracellular action is separate from an antibody’s surface delivery target, such as BCMA or TROP2. Normal cells also use this machinery, so target identity alone does not establish tumor selectivity.
The collateral-vulnerability hypothesis asks whether loss of one POLR2A copy reduces the margin for further suppression. The 2015 colorectal report studied co-deletion near TP53 and amanitin delivery in cell/mouse models. A separate TNBC report used siRNA in nanoparticles. A TP53 mutation does not by itself establish POLR2A copy loss, and these model findings do not establish a clinical eligibility test.
In plain words · POLR2A encodes the largest subunit of RNA polymerase II, which makes RNA from DNA. Researchers study whether losing one gene copy creates a vulnerability to further suppression.
POLR2A encodes the largest subunit of RNA polymerase II, which makes RNA from DNA. Researchers study whether losing one gene copy creates a vulnerability to further suppression.
The approved human gene symbol is POLR2A, at 17p13.1. Its product is part of RNA polymerase II.
No product in this corpus aims at POLR2A yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
The approved human gene symbol is POLR2A, at 17p13.1. Its product is part of RNA polymerase II. DNA copy number, RNA/protein abundance, enzymatic activity and drug response are separate measurements; loss of one copy is different from complete loss or any TP53 sequence alteration.
Query for this target: (TITLE:"POLR2A" OR ABSTRACT:"POLR2A" OR TITLE:"RNA polymerase II subunit A" OR ABSTRACT:"RNA polymerase II subunit A" OR TITLE:"POLRA" OR ABSTRACT:"POLRA" OR TITLE:"RPB1" OR ABSTRACT:"RPB1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POLR2A, not a curated reading list.
Shares Pamlectabart tismanitin, Multiple myeloma.
Shares Pamlectabart tismanitin, Multiple myeloma.
Shares Transcription-inhibitor payloads, Antibody-drug conjugate (ADC).
Shares Transcription-inhibitor payloads, Antibody-drug conjugate (ADC).
Shares Transcription-inhibitor payloads, Antibody-drug conjugate (ADC).
Shares Pamlectabart tismanitin, Multiple myeloma, Antibody-drug conjugate (ADC).
Shares Synthetic lethality, Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/